Dr. Emily Avitan-Hersh

Department of Dermatology and Skin cancer research lab Rambam Health Care Campus

Bio:

Dr. Emily Avitan-Hersh is head of the Department of Dermatology and outpatient clinic at Rambam Health Care Campus.

Dr. Avitan-Hersh graduated (cum laude) from the Rappaport Faculty of Medicine at the Technion, and completed her residency in the Department of Dermatology at Rambam. After her residency she completed a PhD in melanoma research under the supervision of Assoc. Prof. Amir Orian and Prof. Ze'ev Ronai at the Technion faculty of medicine, and won the Wolf foundation prize for excellent students. She also holds a senior lecturer position at the Technion. Her research interests include skin cancers, side effects of immunotherapy and genetic skin diseases.

Title:

Lecture 1:
Nail changes in systemic diseases

Abstract:

Nails are involved in several systemic diseases and sometimes are the first sign. We will discuss nail involvement in systemic diseases.

Prof. Aviv Barzilai

Department of Dermatology, Sheba Medical Center

Bio:

Title:

Abstract:

Dr. Regina Casz Schechtman

Brazilian society of Dermatology, American Academy of Dermatology, International society of Dermatology

Bio:

General Secretary Brazilian Society of Dermatology-Rio de Janeiro Section (2021-2022). Assistant Professor in Dermatology and Mycology at Pontifical Catholic University of Rio de Janeiro, Brazil. Adjunt Professor in Dermatology at State University of Rio de Janeiro, Brazil. 22 Peer-reviewed papers; 38 chapters of books; 1 book; 83 papers presented at conference and 118 invited talks at conference.

Title:

Lecture 1:
Non-dermatophytic Filamentous Fungal Onychomycosis: Reality or Misdiagnosis?

Abstract:

Abstract 1

Filamentous fungi in general constitute a large number of agents that appear in the environment as hyaline or pigmented hyphae, transmitted by inhalation or transcutaneous implantation of infective propagules and have low virulence potential.

In severely immunosuppressed hosts, some filamentous fungi can invade deep structures compromising organs or tissues and causing invasive fungal diseases. Non-dermatophytic filamentous fungi (FFND) are considered a heterogeneous group of fungi that are generally saprophytic, but are implicated in dermatological infectious processes. They mostly cause onychomycosis, but there are also reports of cases of involvement of other topographies, such as skin, scalp and hair. Scientific articles that estimate the prevalence of causal agents of onychomycosis consider that the frequency of involvement by FFND varies between 1% and 20%. Lately, FFND have been considered etiological agents of increasing importance in the context of onychomycosis, especially in countries with hot and humid climates. In Thailand and Jamaica, for example, it is estimated that 10% to 50% of superficial fungal infections are caused by Scytalidium spp.

Prof. C. Ralph Daniel

Clinical Professor of DermatologyUniversity of Mississippi Medical Center and, University of Alabama
USA

Bio:

Nail Disorders 2022 Conference Co-Chair

Undergraduate Education:

Vanderbilt University – 1970-1973
Medical school – University of Mississippi Medical Center – 1973-1977
Medical Internship – University of Mississippi Medical Center – 1977-1978
Residency in Dermatology – University of Alabama, Birmingham – 1978-1981

Leadership positions:

President Council for Nail Disorders, Mississippi Dermatology Society, Jackson Academy of Medicine, St. Dominic’s Health Services Foundation
Vice President European Nail Society
Board of Directors – American Academy of Dermatology, NOAH, American Medical Athletic Association
Published:
1. 6 books on nails
2. Over 120 papers

Title:

Lecture 1: Chronic Simple Paronychia: An Update and the Practical Approach for These Patients

Lecture 2: Onycholysis: An update, and the Practical Therapeutic Approach for These Patients

Abstract:

Abstract 1:

Chronic paronychia is commonly seen in our office practices. It is defined as persisting at least 6 weeks. Staging, studies done by the speaker, and other work will be presented to support proper management of this frequently encountered disorder.

The possible roll of Candida will be presented.

Abstract 2:

Simple onycholysis is frequently encountered in our daily medical practices.

If the process persists, it can be permanent and may lead to the disappearing nail bed.

Studies will be presented to support the proper management of onycholysis.

The possible roll of Candida will also be discussed.

Dr. Tomer Goldsmith

Director of nail clinic, Tel Aviv medical centerDirector of inpatient care, Division of Dermatology, Tel Aviv Medical center

Bio:

Tomer Goldsmith is a graduate of Ben Gurion university of the Negev (summa cum laude), and completed parts of his clinical years at the Albert Einstein medical school, New York. He has completed his residency in dermatology at the Tel Aviv medical center. He then received further training in nail medicine and surgery at CHU Brugmann, Brussels, under the guidance of professor Bertrand Richert.

Upon returning to Tel Aviv Tomer was appointed as head of inpatient service at the Tel Aviv medical center division of Dermatology, In addition to being the director of the nail clinic there, that serves as a referral center to patients with nail problems from all over Israel.

In addition to his clinical practice Dr Goldsmith has also been involved in basic science research in molecular dermatology, studying keratinization disorders and ectodermal dysplasia, as well as various clinical studies.

Title:

Lecture 1: Melanonychia – seeing the full picture

Lecture 2: Ingrown nail treatment: laser vs surgical

Lecture 3: Ingrown nail treatment: laser vs surgical

Abstract:

Abstract 1

Melanonychia is a common condition seen in the dermatology practice. The lecture will deal with the proper diagnostic approach to melanonychia, with special emphasis on when and how should it be surgically excised. Various diagnostic and surgical approaches will be discussed, and common pitfalls explained.

Abstract 2

A literature review of the different treatment variations for onychocryptosis.

Abstract 3

The dark side of the nail – what is the best treatment modality for ingrown nail? This common and debilitating condition affects many of our patients. While surgical treatment methods vary, Laser treatment may offer a relatively new option for cure. Or does it really? We will try to decide – Laser or cold steel? Which modality reigns supreme?

Prof. Shoshana Greenberger

Department of Dermatology, Sheba Medical Center Israel

Bio:

Prof. Greenberger is the director of Pediatric Dermatology service at The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, and an Associate Professor at Sackler faculty of medicine Tel-Aviv University. She received her medical degree from the Hebrew University in Jerusalem and her PhD from Tel‐Aviv University, Israel. After completing her residency in Dermatology at Sheba Medical Center in Israel she was a post‐doctoral fellow at the Children's Hospital Boston and Harvard Medical School. Her clinical interests are pediatric dermatology, inflammatory dermatoses,vascular anomalies and genodermatoses. Her research lab in Sheba Medical Center focuses on pathological angiogenesis and lymphangiogenesis.

Title:

Lecture 1: Nail disorders and Atopic Dermatitis

Abstract:

Shoshana Greenberger

Pediatric Dermatology Service, Sheba Medical Center and Sackler Faculty of Medicine, Tel-Aviv University, Israel

Nail changes in atopic dermatitis (AD) are not well-studied. While nail manifestations are more well-established in psoriasis, nail manifestations in AD are common as well. Changes can be primary, due to AD periungual involvement, secondary to scratching or resulting from other causes such as irritant contact dermatitis and Allergic Contact Dermatitis. As nails play an important functional and aesthetic role, nail dystrophy can negatively impact a patient's life. Therefore, awareness among clinicians regarding this association is important. Key manifestations of AD in nails will be discussed as well as new targeted treatment for this disease.

Prof. Boni Elewski

Professor and Chair, James Elder Endowed Professor of Graduate Medical EducationUniversity of Alabama
USA

Bio:

Dr. Boni Elewski, an Ohio native, started her career at Ohio State University College of Medicine, where she earned her medical degree. She completed an internship in internal medicine and residency in dermatology at University of North Carolina Memorial Hospital, and she held faculty positions at Northeastern Ohio University College of Medicine and Case Western Reserve School of Medicine, before joining UAB faculty in 1999. Currently, Dr. Elewski serves as the Chair for UAB’s Department of Dermatology and the Program Director for the Dermatology Residency Program, where she has been a professor for the past seventeen years. She holds the James E. Elder M.D. Endowed Professorship for Graduate Education. As an international leader in fungal and psoriasis research and dermatological clinical trials, she has conducted clinical trials through her entire career and has received 85 clinical trial study grants to pursue therapies for many dermatologic conditions. Dr. Boni Elewski is the author of more than 300 publications and has an esteemed history of serving in numerous national societies and professional organizations, including president of the American Academy of Dermatology from 2004-2005.

Title:

Lecture 1: Colorful nail pearls- diagnosis of nail disease by nail colors (erythronychia, leukonychia, melanonychia, etc) -

Lecture 2:Antifungal resistance in onychomycosis: What you need to know

Abstract:

Abstract 1

Boni E. Elewski, MD

James Elder Professor and Chair of Dermatology

University of Alabama at Birmingham

Diagnosis of nail disorders can be challenging. Often, however, the color of the nail may be a clue to a particular diagnosis. For example, onycholytic nails with a green hue may indicate a bacterial infection. Black nails (melanonychia) can be caused by tumors such as melanoma, but also by systemic medications such as hydroxyurea. A longitudinal streak that is red in color (erythronychia) on one nail may be indicative of a tumor, but if on multiple nails may be a sign of lichen planus or graft vs host disease. Slow growing nails with a yellowish color are typical of “yellow nail syndrome”. White nails- or leukonychia- may be caused by a variety of systemic conditions and fungal infections. Nails with an orange patch could be from a dermatophyte abscess (dermatophytoma). It is important to recognize nail color changes to correctly diagnose the nail condition.

Abstract 2

Onychomycosis can be treated with a variety of oral and topical antifungal medications. The oral medications include terbinafine, itraconazole and fluconazole and have been available for over three decades. Although griseofulvin is also available in some countries, it is seldom used to treat onychomycosis. Unfortunately, antifungal “resistance” is now common in certain regions. This resistance probably began in the Indian subcontinent where most of the isolates are unfortunately resistant to all of these drugs. One recent study from of tinea corporis in India compared appropriate daily oral dosages of each of these medications in a randomized four-arm trial, and the cure rate was less than 8% at 4 weeks. Only itraconazole had more than a 50% cure rate at 8 weeks. There is concern for endemic spread of resistant dermatophytes. Itraconazole is considered the best option in patients with resistant onychomycosis and topical efinaconazole may be another alternative. Given this situation, aggressive treatment of onychomycosis until the nail is cured may be the best solution going forward.

Dr. Eran Galili

Department of Dermatology, Sheba Medical Center, Tel Hashomer, Israel

Bio:

Eran Galili, MD, received his medical degree from Tel Aviv University. He completed his residency in dermatology at Sheba Medical Center, Israel. Later, Dr. Galili was trained in nail surgery under the supervision of Prof. Eckart Haneke.

Currently, Dr. Eran Galili is a senior physician at Sheba Medical Center where he serves as an attending physician at the nail and fungal skin diseases clinic. He also specializes in laser therapy at Sheba's advanced technology center.

Dr. Galili is a member of the European Nail Society (ENS) and the author of more than 15 peer-reviewed publications.

Title:

Lecture 1: Painful nail- A Quiz

Lecture 2: Emtrix for Onychomycosis- An Update

Abstract:

Abstract 1

Painful nail is a common result of many diseases, including some distinct to the nail apparatus.

While pain may be subjective, some nail diseases are known to be painful, such as ingrown nail and paronychia.

Conditions causing nail pain include, among others, trauma, infection, inflammation and tumors.

Several cases will be present and discussed.

Abstract 2

Emtrix is a once daily topical solution for the treatment of onychomycosis. The presentation aims to briefly review its mechanism and effectiveness.

Prof. Nissim Garti

Full Professor (Emeritus) of Chemistry Ratner Family Chair in Chemistry Lyotropic Delivery SystemsLDS- Founder, Chief Scientist, and Chairman

Bio:

Biography- Nissim Garti

Prof. Nissim Garti is emeritus full professor of chemistry and the previous director of the Casali Center of Applied Chemistry, The Hebrew University of Jerusalem. His long-term projects are on "Lipid-based nano domains delivery vehicles for bioactives in food, cosmetoceuticals and pharmaceuticals applications"

Garti is the founder and the CEO of "drug delivery company –Lyotropic Delivery Systems (LDS)" that developed, patented and commercialized several platform novel delivery vehicles for innovative and generic water-insoluble drugs for enhanced bioactivity.

Garti was announced as a ‘distinguished professor’ and honored and entitled ‘Ratner Family Chair of Chemistry of the Hebrew University’ (from 2011).

In 2013 Garti was recognized as one of the 23 most important inventors and contributors to innovation of the Hebrew University for his contributions in Food Science, Nutraceuticals and Delivery Vehicles for Bioactives and more , and was honored as member of the 'Hall of Fame' of the University Inventors.

Garti was awarded with many international and national prestigious prizes. Among the important awards are: Life-Time Scientific Achievements in Food Science (2015), Surfactants in Solution Society (SIS) (2014), Supelco/Nicolas Pelick Award of the American Chemists Oil society , AOCS (2013) ,“Chang Award” (2011), “Corporate Research Award” of the AOCS (2012); “The International Food Technologists (IFT) Society Award" (2009), Lord Kaye (British) Award (1990 and 2000), the Rockefeller Foundation Award (2004), The Japan Award for Promotion of Foreign Scientists (2004) and more.

Garti was twice the Director of the Casali Institute of Applied Chemistry, and the Director of the Graduate School of Applied Sciences and Technology of the Hebrew University. He served (2010-2013) on the Management Committee (Board of Directors) of the Hebrew University.

98 MsC and 60 PhD students graduated under his direct supervision.

Garti’s scientific achievements include 410 "publications", in peer reviewed journals, 14 edited books , 85 chapters in books and 110 patents.

In the last 6 years Garti devoted much of his time in establishing new strat-up (Lyotropic Delivery Systems (LDS ltd), and was a key person in establishment based on his technology "Neoprol" (IV delivery of propofol), "OphRX" (ophthalmic cyclosporine ), Ananda (for oral CBD), "Nanovate" (for nails fungi), and confidential drug foron of the biggest global pharma company - confidential

In the last year, Garti developed and patented novel "thin films embedded with nanodomains loaded with drugs to serve as patch for sustained and slow release delivery tool".

Title:

Lecture 1: Novel nano domains and film forming technology as delivery vehicles for the treatment of nail fungal infections

Abstract:

Nissim Garti, Rotem Edri, Sharon Garti-Levi,

*Casali Center of Applied Chemistry. The Hebrew University of Jerusalem

**LDS –Lyotropic Delivery Systems,

Hitech Campus, Givat Ram, Jerusalem

In recent years a very significant effort is made to design and produce effective novel nano delivery vehicles for insoluble, as well as biopolymers and chemically sensitive pharmaceuticals. The number of generic or innovative bioactives with very limited bioavailability and poor performance is very significant and as a result many drugs have shown poor performance. It is well recognized that poor performance can be because of poor bioavailability, or chemical instability.

We will report in this presentation on novel and patented "Molecularly Engineered Modified Liquid Nano Domains and films " for enhanced bioavalability and controlled release of drugs used for treatment of fungal infections (onychomycosis).

The results of these nano liquid structures led to the establishment of Lyotropic Drug Delivery Labs (LDS) showing promise in solubilization, and membrane crossing (including nails) of generic pharmaceuticals.

Some of the major advantages of the novel molecular architectures spontaneous formation, self-assembled (NSSL) and their full dilution in aqueous phase, thermodynamic stability, and monodispersibility (ca 15 nm) with, high loading domains capacity including the ability to permeate through, and across human nails and treat fungi onychomycosis. Preclinical studies have shown excellent results including full cure. The formulations are presently tested clinically in an Israeli Hospital.

Dr. Shamir Geller

Division of Dermatology, Tel Aviv Sourasky Medical Center, Israel

Bio:

Shamir Geller, M.D.

Director of the Dermatology Outpatient Clinics, Division of Dermatology, Tel Aviv Sourasky Medical Center, Senior clinical lecturer, Sackler Medical School, Tel Aviv University, Tel Aviv, Israel

Shamir Geller received his MD from Tel-Aviv University. He specialized in dermatology at Tel-Aviv Sourasky Medical Center (TASMC). He spent a research fellowship at the Dermatology and Allergology Department in the Universitätsklinikum Gießen und Marburg, Germany studying novel diagnostic methods in autoimmune blistering diseases. He spent three years at Memorial Sloan Kettering Cancer Center, New York, USA for a cutaneous oncology fellowship focusing on cutaneous lymphoma. Upon his return to Tel-Aviv, he became the director of the outpatient dermatology clinics and a senior physician in the cutaneous lymphoma clinic at TASMC. He has co-authored almost 60 scientific publications, has mentored students and residents. His research focuses on diagnostic techniques and epidemiology of lymphomas of the skin and other skin cancers.

Title:

Lecture 1:
Nail Irregularities Presenting in Patients with Cutaneous T-Cell Lymphoma: A Systematic Review of the Literature

Abstract:

Abstract 1

Irregularities of the nails in patients with cutaneous T-cell lymphoma (CTCL) are frequently overlooked and underreported. Nail irregularities may be seen in advanced-stage mycosis fungoides (MF) and in Sezary syndrome (SS), the most common CTCL subtypes of cutaneous T cell lymphoma, and rarely in early stages of the disease. Nail abnormalities in CTCL may be related to the underlying disease, to superimposed infection or due to therapy, specifically phototherapy, PUVA, radiation, and chemotherapy. The spectrum of nail changes in SS patients include nail thickening, onychodystrophy, yellow discoloration, subungual hyperkeratosis, onychomadesis, trachyonychia, onycholysis, paronychia and leukonychia. Nail changes have been reported to be present in 30% of all MF patients with longitudinal ridging, nail thickening, nail fragility, and leukonychia being the most common nail irregularities seen in MF patients. Based on our experience and the literature, nail irregularities in patients with MF and SS are heterogenous, are not uncommon, and may be used as a clinical clue of CTCL diagnosis. Further studies are needed to better understand nail involvement in CTCL and its treatment.

Prof. Aditya K. Gupta

Department of Medicine (Division of Dermatology), University of Toronto, Canada

Bio:

Aditya K. Gupta, MD, received his medical degree from the University of Southampton, UK. He completed a dermatology residency/clinical research fellowship at the University of Michigan, Ann Arbor, and has received a PhD from the University of Göteborg, Sweden. Dr. Gupta is a Professor of Dermatology at the University of Toronto. Dr. Gupta has a well-established dermatology practice in London, Ontario, Canada specializing in but by no means restricted to the field of onychomycosis, which also contains a clinical trials unit. Dr. Gupta’s reputation in the field of mycology has been achieved throughout his career. Dr. Gupta has over 800 publications, is on 15 journal editorial boards, and reviews for over 35 journals. He is a Diplomate of the American Board of Dermatology; he is also a Fellow of the American Academy of Dermatology.

Title:

Lecture 1:
Antifungal Resistance – Should we be concerned?

Lecture 2:
An Update on Antifungals to Treat Onychomycosis

Abstract:

Abstract 1:

This presentation will describe dermatophytosis epidemiology and changes seen relating to treatment resistance. The evolution of resistance is described, including factors in resistance development. Treatment for dermatophytosis is reviewed, including resistant dermatophytosis. There are many newer therapies which may assist in resistant infections, either as monotherapy or in combination with traditional antifungal agents. Strategies to prevent resistance can be implemented, including susceptibility testing of causative agents. Increased resistance indicates a need for antifungal stewardship programs for dermatophytosis: principles of stewardship will be discussed.

Abstract 2:

The common oral antifungal agents used to treat onychomycosis are terbinafine and itraconazole. Recently there have been reports of poor response or resistance to oral terbinafine. Use of the newer antifungals (voriconazole, posaconazole, albaconazole, fosravuconazole, and oteseconazole) will be discussed. Topical agents will be reviewed. Antifungal prophylaxis and stewardship will also be briefly presented. Recommendation for the most appropriate dosing regimens, and guidelines for monitoring, will be reviewed for both common topical and oral agents and the newer agents.

Prof. Eckart Haneke

Department of Dermatology, Inselspital, University Bern, Switzerland

Bio:

Study of medicine at the Medical Faculty, Martin-Luther-University Halle-Wittenberg in Halle/Saale 1960-1966

Internship in Internal Medicine, Surgery (traumatology), and Physiological Chemistry 1966-1967

Dermatology training at Dept Dermatol, Martin-Luther-University Halle 1967-1971, board certification 1971

Senior resident till Jan 1973

General practitioner at Arnstein/Unterfranken 1973-1974

Dept Dermatol Univ Erlangen 1975-1986: Senior resident 1975, Ass Prof 1975-1978, Docent 1978-1979, Associate Prof 1980-1986

Professor and chairman, Dept Dermatol Wuppertal Hosp, Acad Teaching Hosp Univs Düsseldorf and Witten-Herdecke 1986-2000

Head, Inst Dermatol, Klinikk Bunaes, Sandvika, Oslo, Norway 2000-2004

Dermatologist, Dermatol Clin „Dermaticum“, Kaiser-Joseph-Strasse, Freiburg, Germany, since 2004

Honorary Consultant, Dept Dermatol, Univ Med Ctr St Radboud, Nijmegen, Netherlands, 2004-2005

Visiting professor, Dept Dermatol, Univ Berne, Switzerland, since 2005

Senior Consultant, Dept Dermatol, Acad Hosp, Univ Ghent, Belgium, since 2006

Senior Consultant, Centro de Dermatologia, Instituto CUF, Porto, Portugal, since 2008

MD: Univ Halle 1968 (Thesis: Fluorescence histochemical demonstration of adrenergic nerves in the portio vaginalis uteri)

PhD: Univ Erlangen 1978 (PhD Thesis: Glossodynia – clinical, histopathological, histomorphometric measurements, aetiopathogenetic management)

Associate professor: Erlangen 1979

Clinical professor: Erlangen 1980

Special interests

Dermatopathology, dermatological surgery, nail diseases, diseases of the oral mucosa, aesthetic dermatology

Publications

>400 journal articles, >190 book chapters, author of 8 books, co-editor of 10 books, >1600 lectures at national and international meetings

Reviewer for Arch Dermatol/JAMA Dermatol, Br J Dermatol, Eur J Dermatol, Hautarzt, J Am Acad Dermatol, J Eur Acad Dermatol Venereol, J German Soc Dermatol, Fungi, J Cut Pathol, etc.

Member of the editorial board of several peer-reviewed journals

Advisory Board: Dermatol Med Quir Cosm, J Turk Acad Dermatol

>30 dermatol surgery courses in 5 continents

>25 nail surgery courses in 4 continents

Societies

German Dermatol Soc, German Soc Dermatol Surg (Founding member, long-term board of directors, past vice-president), Eur Acad Dermatol Venereol, French Soc Dermatol Venereol (Corresponding Member), Austrian Soc Dermatol (Corresponding member), German Working Group Dermatohistopathol (Past President), Asoc Colomb Dermatol (Honorary member), German Mycol Soc, Mex Soc Dermatol Surg (Hon Member), Turk Dermatol Soc (Hon Memb), Pol Soc Dermatol (Hon Memb), Int Soc Dermatol Surg (Past President), Eur Nail Soc (Past President), Eur Soc Cosm Aesthet Dermatol (Past Pres), Dermatol Surg Group Swiss Soc Dermatol Venereol (Hon Member), Asociación Argentina de Medicina y Cirugía Cosmética (Hon Member), Hellenic Soc Dermatol Surg (Hon Member), Romanian Soc Dermatol (Hon Member), Swiss Soc Dermatol Venereol (Corresponding Member), Slovak Soc Med Branch of Aesthet Cosm Dermatol (Honorary Member), Swiss Soc Dermatol Venereol (Honorary Member), Roman Soc Dermatopathol (Honorary member), Soc Mex Tricol (Honorary Member).

Title:

Lecture 1: Longitudinal Melanonychia with or without Hutchinson's Nail Sign and Different Nail Pigmented Lesions, from where Exactly Should the Biopsy be taken?

Lecture 2: Surgical approach for retronychia

Lecture 3: Conservative and/or Surgical Approach for Pincer Nails and Ingrown Toenails

Abstract:

Abstract 1:

Longitudinal Melanonychia with or without Hutchinson's Nail Sign and Different Pigmented Nail Lesions - from where Exactly Should the Biopsy be taken?

Eckart Haneke

Department of Dermatology, Inselspital, University of Berne, Bern, Switzerland

Dermatology Practice Dermaticum. Freiburg, Germany

Centro de Dermatología Epidermis, Instituto CUF, Matosinhos, Porto, Portugal

Nail pigmentations are always of concern as approximately three quarters of nail melanomas start with a brown to black longitudinal band in the nail. However, a longitudinal band due to melanin can only develop when there is a melanocyte focus in the matrix producing more melanin than the matrix keratinocytes can physiologically degrade. Thus, a biopsy has to be taken from the matrix and not from the nail plate or the nail bed. Any melanocyte lesion in the nail bed even when producing excess melanin cannot give the pigment into the nail plate and will thus only be visible as a dark spot under the nail and not as a brown streak.

Hutchinson’s sign is periungual pigmentation due to abnormal melanocyte activity or number. This periungual pigmentation although described in 1886 by Sir Jonathan Hutchinson as “melanotic whitlow” in association with “melanotic sarcoma” can be observed in also other lesions, both benign and malignant. Thus nowadays, benign and malignant periungual pigmentation is differentiated and the malignant one may be due to melanoma or Bowen’s disease. The cellular alterations seen in Hutchinson’s sign may be very subtle and their exact recognition requires a lot of experience by the dermatopathologist as well as good clinico-pathologic correlation. Pigment shining through the thin cuticle and free margin of the nail fold is called pseudo-Hutchinson. Both Hutchinson and pseudo-Hutchinson sign must be differentiated from non-melanin pigmentation.

These facts explain why a biopsy of longitudinal melanonychia both without and with Hutchinson’s sign has to be taken from the matrix and not from the nail bed or periungual pigmentation.

Abstract 2:

Surgical approach for retronychia and onychomycosis

Eckart Haneke

Department of Dermatology, Inselspital, University of Berne, Bern, Switzerland

Dermatology Practice Dermaticum. Freiburg, Germany

Centro de Dermatología Epidermis, Instituto CUF, Matosinhos, Porto, Portugal

Retrograde ingrowing of the proximal nail plate is called retronychia. It was only described 23 years ago, and it took another 10 years before 12 more cases had been described. Now, far more than 200 cases have been reported.

Three different types of retronychia can be distinguished. The least frequent but most impressive type occurs after a single heavy trauma that disrupts the attachment of the plate to the matrix (and nail bed) and pushes the nail back into the nail pocket. The proximal nail margin pierces the skin in the depth of the cul-de-sac, which leads to granulation tissue. The nail does not regrow properly forward but builds up stacks of new nail due to repeated traumatic separation of the nail from the matrix.

The commonest type is due to repeated trauma, which leads to very marked onycholysis. This allows the nail to be pushed back with each compression thus loosing its attachment to the matrix. Each backward movement causes a horizontal fracture of the nail from the matrix and the lack of nail bed attachment causes a new nail layer to be formed until many layers of nail are laid one upon the other. The oldest proximal nail margin hardens and its margin becomes very hard and sharp cutting into the undersurface of the proximal nail fold. This is eventually pierced giving rise to granulation tissue, which may even protrude from under the free edge of the nail fold.

Another not well-known type is the chronic non-inflammatory retronychia. The nail is discolored, markedly curved in its longitudinal axis, its surface shows multiple deep transverse arched splits making the nail look like a horse-shoe crab or back of a shrimp. Close inspection of the toe reveals a marked onycholysis, and a huge distal bulge that is often barely visible under this malformed nail. Cutting away the non-adherend nail reveals a tremendously shortened nail bed, which is deeply depressed.

The treatment of choice of retronychia is nail avulsion in the two first types followed by consistent taping to hold the hyponychium and distal nail bed down. In mild cases, topical steroid may be tried or intralesional steroid injection.

Onychomycosis is a fungal infection of the nail apparatus. Contrary to common belief it is in most cases not the nail plate that is infected but the nail bed. The commonest variant, the distal-lateral onychomycosis, makes up for more than 85% of all onychomycoses. Here, the pathogenic fungus invades the nail bed from the tip of the digit via the hyponychium. The infected nail bed responds to the irritation by the infection with the development of nail bed hyperkeratosis where the vast majority of the fungi is found. The fungus can only slowly advance further proximal against the direction of growth of the nail plate. At times when no efficacious antifungal drugs were available nail avulsion was often performed; however this is a useless torture for the patient as this “treatment” is based on the wrong assumption that the nail plate is the target of the fungus. Once the nail plate has been avulsed there is no counter-movement by the nail anymore and the fungus can spread rapidly. Further, nail avulsion is the most severe iatrogenic nail trauma, and it is known that trauma is one of the most important predisposing factors the development of onychomycoses. Nail avulsion may very rarely be of benefit but only as the start of an intensive antifungal therapy.

Abstract 3:

Conservative and/or Surgical Approach for Ingrown Toenails and Pincer Nails

Eckart Haneke^1,2,3 & Anna Stovbyr⁴

¹Department of Dermatology, Inselspital, University of Berne, Bern, Switzerland

²Dermatology Practice Dermaticum. Freiburg, Germany

³ Centro de Dermatología Epidermis, Instituto CUF, Matosinhos, Porto, Portugal

⁴Klinik Evroderm, Kiew, Uktaine

Ingrown toenails (unguis incarnatus, onychocryptosis) and pincer nails (transverse overcurvature, trumpet nail, omega nail, unguis constringens) are very common. Ingrown toenail occur in different clinical varieties and at any age.

In the newborn, they are due to short nails that have not yet overgrown the tip of the big toe. They are treated by gentle massage of the toes in warm bath.

A hypertrophic lateral or medial lip is an inborn hypertrophy of one or both lateral nail folds. Again, the first treatment is gentle massage. If this is not successful, the hypertrophic fold may be removed with an electric loop, which takes some seconds to do. The small wound rapidly heals by secondary intention.

Congenital malalignment of the big toenail is not so rare. The nail’s long axis is deviated laterally in relation to the axis of the distal phalanx. This may have no further consequences or may be associated with discoloration of the nail, transverse ridging, thickening of the plate, a triangular shape with medial kinking of the plate. In these cases, gently probing under the plate reveals very marked onycholysis, which is the single most important prognostic factor. Cutting the onycholytic plate back demonstrates a distal bulge and an extremely short nail bed. The initial treatment should be conservative with taping to redress the distal bulge, correct the distal interphalangeal hallux valgus and the nail growth direction. If this is done by the parents there is a very good chance of improvement. When this fails after consistent treatment of at least two years surgery may be performed to rotate the axis of the nail into that of the distal phalanx.

The most common type of unguis incarnatus is seen in school children, adolescents and young adults. The nail is wide, usually markedly curved, the lateral-distal edge has pierced the distal nail groove and caused granulation tissue. Conservative therapy is by taping, packing, gutter insertion, nail braces and many more techniques and has a good success rate when performed consistently. However, patient counseling to avoid recurrences is of utmost importance. If this fails surgery is indicated. In our hands and now world-wide, narrowing of the nail plate by selective segmental matrix horn ablation is the treatment of choice. This may be done by chemical cautery with 88% phenol, which has a success rate of 99% in experienced hands. Altrnatives are 10% sodium hydroxide and 85 – 100% trichloracetic acid. The postoperative care is very important as this is what has the biggest influence on the healing time. If there is a very marked hypertrophy of the lateral nail folds, they may be reduced with radical excision according to Vandenbos or with the super-U technique. These techniques do not narrow the nail matrix.

Pincer nails are characterized by a distally increasing transverse overcurvature of toenails. The genetic type shows symmetric involvement of the big toenails associated with lateral deviation and often also of some lesser toenails then associated with medial deviation. The cause is a widening of the base of the distal phalanx by lateral osteophytes on the condyles of the distal phalanx. In mild forms, unbending the nails with nail braces and a variety of other orthonyx devices is helpful. However, as this is not a therapy according to the pathomechanism the braces have virtually to be kept years if not life-long. Surgery of moderate cases aims at taking the outward pressure on the root of the nail away by bilateral matrix horn cautery. Severe cases require an additional nail bed plasty to flatten the pinched nail bed. If the curvature exceeds 360° and is symptomatic complete nail phenolization may be performed.

Dr. Nir Nathansohn

Israeli Mole Mapping Center, Israel

Bio:

Dr. Nir Nathansohn, MD MHA received his medical degree and Master Of Health Administration degree from Ben Gurion University at Beer Sheba. He completed his residency in dermatology at Sheba Medical Canter, Israel and served as the IDF’s chief dermatologist. Dr. Nathansohn pioneered the use of dermoscopy in Israel since 1997 and established the first mole mapping clinic in Israel in 2004. . His main interests are dermoscopy and early detection of melanoma by mole mapping.

Title:

Lecture 1: Nail Dermoscopy: Highlights and Pitfalls

Abstract:

Dermoscopy of the nail unit has an important role in diagnosing nail disease. In this lecture I will cover recent data from the literature and highlight major pitfalls that one should be aware of in performing nail dermoscopy.

Dr. Felix Pavlotsky

Sheba Medical Center, Tel Hashomer, Israel

Bio:

Graduate of Faculty of Medicine, the Hebrew University of Jerusalem, Israel
Residence in Oncology and Dermatology
Head of Psoriasis and Phototherapy Center, Dermatology, Chaim Sheba Medical Center, Tel- Hashomer, Israel.
Senior lecturer at Sackler Faculty of Medicine, Tel Aviv University, Israel
Head of the Israeli Dermatology Board Committee

Title:

Lecture 1: The Efficacy of Phototherapy and Laser Treatments of Nail Psoriasis

Abstract:

Abstract 1:

Phototherapy is well established and highly effective therapy of skin psoriasis. However, due to limited ultraviolet penetration through the nail plate, the management of the nail involvement is more challenging.

Thus, longer wavelengths (UVA, lasers) and/or higher energy (XRT) sources are used with variable results. The role of photo-, radio- and laser therapy in the modern management of the nail psoriasis will be discussed.

Dr. Lev Pavlovsky

Rabin Medical Center, Israel

Bio:

Dr. Lev Pavlovsky has graduated from the Ben-Gurion University of the Negev Medical School, MD Ph.D. program.
He completed a residency in dermatology at Rabin Medical Center and was trained in phototherapy and psoriasis in the Department of Dermatology, Mount Sinai School of medicine in New York under the supervision of prof. Mark Lebwhol.
Currently, he is the director of the psoriasis treatment service and the outpatient clinics in the Division of Dermatology at Rabin Medical Center, Petah-Tikva, Israel. His field of expertise is immunobiological treatments of psoriasis. During his work in Rabin Medical Center, he has led numerous international clinical trials in this field. He is a secretary of ISDV and the Israeli association for psoriasis and national representee in SPIN network. He has authorized more than 45 scientific publications and book chapters.

Title:

Lecture 1: Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis

Abstract:

The lecture will review the literature on network meta-analyses in the field of biological therapies for nail psoriasis. We will discuss the advantages and the limitations of these publications and their possible impact on our clinical practice.

Dr.Vered Molho Pessach

Department of Dermatology, Hadasah, Medical Center, Jerusalem, Israel

Bio:

Vered Molho-Pessach, MD

After concluding her Dermatology residency at the Department of Dermatology of Hadassah- Hebrew University Medical Center in Jerusalem, Israel in 2009, Dr. Vered Molho-Pessach performed her fellowship in Pediatric Dermatology at the Department of Dermatology, New York University, NYC. Later, in 2011, Dr. Molho-Pessach was a research fellow at Dr. Helen Hobbs laboratory at the McDermot Center for Human Genetics, University of Texas Southwestern Medical Center, Dallas, TX. During the last ten years Dr. Molho-Pessach has been working as a senior dermatologist at the Department of Dermatology of Hadassah-Hebrew University Medical Center. She is Head of the Pediatric Dermatology Service at the Hadassah-Hebrew University Medical Center. Dr. Molho-Pessach serves as the treasurer of the Israeli Dermatological Association and as the secretary of the Israeli Pediatric Dermatology Society. She is a senior lecturer at the Hebrew University Faculty of Medicine.

Title:

Lecture 1:
Common Pediatric Nail Disorders

Abstract:

Vered Molho-Pessach¹

¹Pediatric Dermatology Service, Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel

Nail disorders are common in children. Some are normal variants and some are due to pathological processes in the nail unit. The latter may be infectious, inflammatory, proliferative, congenital or traumatic. In this lecture I will review the most common pediatric nail disorders; their clinical features, etiology, clues for diagnosis and management.

Prof. Bianca Maria Piraccini

Dermatological Unit Alma Mater Studiorum University of Bologna, Italy

Bio:

Prof. Bianca Maria Piraccini

Professor in Dermatology, University of Bologna, Ialy

Head of the Dermatological Unit Alma Mater Studiorum University of Bologna, Italy

President of the European Hair Research Society

Past-president of the European Nail Society

Prof. Piraccini is the author of 382 Journal articles (of which 348 on PubMed), 45 Chapters of Volumes and 11 monographs on dermatological diseases.

She has participated in and participates in numerous national and international congresses and courses where she is often a speaker.

Title:

Lecture 1:
Nail Dermoscopy

Lecture 2:
Nail Lichen Planus – Practical Therapeutic Approach

Abstract:

Abstract 1

Bianca Maria Piraccini

Division of Dermatology

Department of Experimental, Diagnostic and Specialty Medicine-, University of Bologna, Bologna, Italy

The use of dermoscopy in nail disorders (also known as ‘onychoscopy’) is quite recent. Initially utilized for the study of nail pigmentations, nail dermoscopy has gradually become more and more frequently used to observe other types of neoplastic and non- neoplastic nail disorders.

The particular anatomy of the nail apparatus makes dermoscopy nor easy to perform and difficult to be interpreted. In most of the cases, dermoscopy only enhances signs already visible with the naked eye, acting only as an illuminated magnifying lens, but the features it shows are anyway very fascinating and unique.

All nail symptoms can be observed by dermoscopy, which enhances visualization of details and may help the diagnosis.

Abstract 2

Bianca Maria Piraccini

Division of Dermatology

Department of Experimental, Diagnostic and Specialty Medicine-, University of Bologna, Bologna, Italy

Nail lichen planus is a benign inflammatory disorder of unknow etiology that may present as an isolated variant or associated with other parts of the body such as skin, scalp and mucosae. Nail lichen planus may induce a scarring outcome if the diagnosis and the treatment are delayed. Therefore, prompt diagnosis and treatment are essential. The choice of therapy is difficult and selected on the basis of the different manifestations. In addition, recurrence is high. Clinically nail lichen planus may have different presentation depend on whether the inflammation is in the nail matrix, nail bed or both. Until now, it cannot be definitely diagnosed without a nail biopsy. Onychoscopy may be useful to better observe nail plate alterations that makes nail matrix or nail bed more likely. No guidelines exist for the treatment of nail lichen planus and published literature is limited to case series and expert opinions. Treatment of nail lichen planus is based on steroids, which can be locally injected if 1-3 nails are involved, or are prescribed systemically. Treatment should last 4-5 months and then be tapered off. Fingernails respond quicker then toenails, which may remain thickener for a long time. The prognosis of lichen planus is variable. 1/3 of the patients do not respond to therapy. A possible alternative for these cases may be immunomodulating therapy or etanercept as biological treatment.

Dr. Michal Ramon

Rambam medical center,Haifa,Israel

Bio:

CURRICULUM VITAE AND LIST OF PUBLICATIONS

CURRICULUM VITAE

PERSONAL DETAILS

Name: Michal Ramon, M.D.

Present Appointment: Senior Dermatologist, in charge of the phototherapy and psoriasis day care center and clinical research

Department of Dermatology,

Rambam Health Care Campus

8 Ha'Aliya St.,POB 9602,

Haifa, 31096 Israel.

Date and Place of Birth: November 13,1958; Haifa , Israel.

Family Status: Married + 3.

Citizenship and Identity Card Number: Israeli 5545998-6.

Passport Number: 32972287

Permanent Home Address: 51 Margalit st., Haifa, Israel 3446429.

Home Telephone Number: 04-8343271, 050-2063228

Telefax Number: 04-8263524

E-mail : m_ramon@rambam.health.gov.il

Michalramon14@gmail.com

EDUCATION

Education: Eironi G, Haifa. Graduated in 1976.

Medical Education: The Technion - Faculty of Medicine, Haifa, Israel.

1976 - 1982.

Academic Degree: M.D., The Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, 1989.

Certifications: Med. Licencse # 020280, 1989.

ECFMG #414-579-3.

Board Certified Dermatologist, March,20, 1995.

#14168

GCP training - Haifa university - 2008

Post Graduate Training:

1/1983 - 1/1984 Internship, Haemek, Central Hospital, Afula, Israel.

2/1984 - 3/1989 Service in the Medical Corps, Israel Defense Forces.

3/1989 - 3/1990 Resident in Anesthesiology, Rambam Medical Center.

4/1990 - 3/1995 Residency in Dermatology, Rambam Medical Center.

6/1993 Israel Board Examination in Dermatology, Stage A.

11/ 1994 Israel Board Examination in Dermatology, Stage B.

2007-2008 Clinical trials management, Haifa university

Appointments:

1989 - 1990 Residency in Anesthesiology.

1990 - 1995 Residency in Dermatology.

1998-2002- Lt. Cdr., Medical Corps, Israel Defense Forces (I.D.F.).

Teaching Experience:

1986 - 1988 Lectures and instruction to Medical personnel in the I.D.F.

- 2021 Teaching courses in dermatology to medical students,

Department of Dermatology, Faculty of Medicine, Technion -

Israel Institute of Technology, Haifa, Israel

1998-2019 Instruction of nurse students in Dermatology.

2000- 2019 Lectures in post graduate courses in dermatology,

Medical school, Tel Aviv University

2002-2004 Lectures in dermatology for post graduate family physicians

Haifa University

Research Experience:

1992-1993- Clinical research on onychomycosis

1993 - 1994 - Clinical research on Kaposi's Sarcoma.

1996-1998 – Clinical research on acne vulgaris

1996-1997 - Clinical research on Herpes simplex and Herpes Zoster infections.

1998-current - Clinical research on Psoriasis

2002- current – Clinical research on epidermolysis bullosa

2002- current - Clinical research on pemphigus vulgaris

2018-current- clinical research on alopecia areata

2016-current- clinical research on atopic dermatitis

Administrative Experience:

Coordination and management of large scale projects during military service.

Service as Chief Physician of women soldier of North Israel Defense forces .

Service as Chief Physician of Haifa recruitment office.

Management of out patient military clinic

Management of clinical trials in dermatology

Advisory board participation

2013-current :Psoriaisis treatment

2015 - Hidtradenitis treatment

2016- cutaneous T cell lymphoma treatment

2018- solar keratosis

2018-Atopic dermatitis

Membership in prefessional Societies :

1996- current Israel Medical Association.

1996-current Israel Soceity of Dermatologyl and Venerology

Society.

2011-current Israeli society of psoriasis

1996-current International society of Dermatology and venerology

1996-current Member of the American Academy of Dermatology

ME# 00000071786

Member of the American Photodermatology society

Member of Woman Dermatology society

2018- current- European society of dermatoloy and venerology

Active Participation in International Conferences:

1. 18th world congress of Dermatology, New-York, 1992.

Paper: Mutilating Hypertrophic Lupus Vulgaris in an Ethiopian new immigrant.

M. Ramon, O. Biterman, S. Weltfriend, R. Bergman & R. Friedman-

Birnbaum.

2. Annual Meeting of the American Academy of Dermatology, San-Francisco, 1997.

3. Biology and Therapy of Inflammatory Skin Diseases: An International Symposium

at the Dead Sea. November, 1997.

Poster: Corticosteroids and Cyclosporin as an Initial Therapy in Pemphigus Vulgaris:

Compared to Conventional Therapy.

M. Ramon, R. Friedman-Birnbaum & R. Bergman.

4. Annual Meeting of the American Academy of Dermatology, Orlando, 1998.

Poster: Hyperbaric Oxygen (HBO) Therapy for Lower Limb Wound Complication

at the Vein Donor Site After Coronary Artery Bypass Graft Surgery.

Y. Ramon, Y. Melamed, A. Shupak, M. Ramon and I. J. Pel

Active Participation in National Conferences:

1. The Annual Meeting of Israel Dermatological Society, 1991.

a. Paper: A Clinical study of Erithrodermic patients during the last twenty

years in the department of Dermatology, Rambam Medical Center/

L. Zuker, R. Bergman, M. Ramon, & R. Friedman-Birnbaum.

b. Paper: Granulomatous Rosacea

M. Ramon , R. Bergman & R. Friedman-Birnbaum.

c. Paper: Fox-Fordyce Disease.

M. Ramon , R. Bergman & R. Friedman-Birnbaum.

2. The Annual Meeting of Israel Dermatological Society, 1992.

a. Paper: Myasis caused by Dermatobia Hominis.

M. Ramon , D. Mertzbach, O. Biterman & R. Friedman-Birnbaum.

b. Paper: Muir-Torre Syndrome.

M. Ramon , B. Zamir, O. Biterman & R. Bergman.

c. Paper: The importance of patch test readings beyond day two.

M. Ramon , S. Weltfriend & R. Friedman-Birnbaum.

3. The first national conference of the Israeli Society of Vulvovaginal Disease,

Herzeliya, 1992.

Paper: Papular acantholytic dyskeratosis of the vulva.

R. Bergman, M. Friedman, I. Kats, M. Ramon, & R. Friedman-Birnbaum.

4. The Annual Meeting of Israel Dermatological Society, 1993.

Paper: Dystrophic calcinosis Cutis.

M. Ramon, R. Bergman, Y. Ullmann, I. J. Peled, G. Elroi & R. Friedman-

Birnbaum.

5. The Annual Meeting of Israel Dermatological Society, 1994.

a. Paper: Pemphigus Vulgaris treated by Cyclosporin and Prednison - Three

year follow-up.

M. Ramon , R. Bergman & R. Friedman-Birnbaum.

b. Paper: Prognostic factors in Kaposi's Sarcoma.

M. Ramon & R. Friedman-Birnbaum.

6. The Annual Meeting of Israel Dermatological Society, 1995.

a. Paper: Immuno histochemical expression of P53 in Kaposi's Sarcoma.

M. Ramon , R. Bergman, S. Kilin, C. Lichtig & R. Friedman-Birnbaum.

b. Paper: Lymphomatoid Papulosis.

A. Dascalu, R. Bergman, M. Ramon & R. Friedman-Birnbaum.

c. Paper: Self Regressing Primary Cutaneous CD30+ Large Cell T-Cell

Lymphoma.

D. Faclieru, R. Bergman, M. Ramon & R. Friedman-Birnbaum.

d. Paper: Perilesional Injection of GM-CSF for Kaposi's Sarcoma.

M. Ramon , R. Bergman & R. Friedman-Birnbaum

LIST OF PUBLICATIONS

1. Ramon M.

Actigraphic sleep patterns in normal pregnant women in comparison to a

control group. ( M.D. Thesis).

2. Dystrophic calcinosis Cutis. European Journal of Plastic Surgery, 1995.

M. Ramon, R. Bergman, Y. Ullmann, I. J. Peled, G. Elroi & R. Friedman-

Birnbaum.

3. An immuno histochemical study of P53 protein expression in classical Kaposi's

Sarcoma.

R. Bergman, M. Ramon , S. Kilin, C. Lichtig & R. Friedman-Birnbaum.

S. Am J. Dermatopathol. 18(4) : 367, 1996.

4. Bergman R., David R., Ramon Y., Ramon M., Kerner H., Killim S., Peled I.

& Friedman-birnbaum R.

Delayed postburn blisters: an immuno-histochemical and ultrastructural study.

J. cutan. Pathol. 24:429-433 , 1997.

5.Sprecher E, Bergman R, Szargel R, Raz T, Labay V, Ramon M, Friedman-Birenbaum,Cohen N

6.Atrichia with papular lesions maps to 8p in the region containing the human hairless gene.

Eli Sprecher^{1 2}, Reuven Bergman¹, Raymonde Szargel², Tal Raz², Valentina Labay², Michal Ramon¹, Ruth Baruch-Gershoni³, Rachel Friedman-Birnbaum¹, Nadine Cohen¹

American journal of medical genetics 80:546-550 1998.

7.Leishmania tropica in northern Israel: A clinical overview of an emerging focus , 07 September 2005
Ayelet Shani-Adir, Stephanie Kamil, Dganit Rozenman, Eli Schwartz, Michal Ramon, Lucia Zalman, Abed Nasereddin, Charles L. Jaffe, Moshe Ephros
Journal of the American Academy of Dermatology
November 2005 (Vol. 53, Issue 5, Pages 810-815)

8. Clinicopathologic reassessment of non-mycosis fungoides primary cutaneous lymphomas during 17 years (p 735-743)
Reuven Bergman, Bat-Sheva Marcus-Farber, Lena Manov, Ina Nerodinisky, Ron Epelbaum, Dvorah Sahar, Rinat Schein-Goldschmid, Michal Ramon, Yehudith Ben-Arieh

Int j dermatol Volume 41 Issue 11 , Pages 721 - 826 (November 2002)

9.Phenotypic Diversity and Mutation Spectrum in Hypotrichosis with Juvenile Macular Dystrophy

Margarita Indelman, Christian P Hamel^†, Reuven Bergman, Ken K Nischal^‡, Dorothy Thompson^‡, Marie-Odile Surget^†, Michal Ramon, Hatam Ganthos^*, Benjamin Miller^*, Gabriele Richard^§, Raziel Lurie^¶, Rina Leibu^*, Isabelle Russell-Eggitt^‡ and Eli SprecherJournal of Investigative Dermatology (2003) 121, 1217–1220;

Journal of Investigative Dermatology advance online publication 27 August 2009; doi: 10.1038/jid.2009.265

10.Insulin-Like Growth Factor-Binding Protein 7 Regulates Keratinocyte Proliferation, Differentiation and Apoptosis

Janna Nousbeck^1,2, Ofer Sarig², Nili Avidan¹, Margarita Indelman³, Reuven Bergman³, Michal Ramon³, Claes D Enk⁴ and Eli Sprecher^1,2

11.Low Dose Methotrexate Therapy is Effective in Late-Onset Atopic Dermatitis and Idiopathic Eczema

Lilach Zoller MD, Michal Ramon MD and Reuven Bergman MD• Israeli journal of dermatol Vol 10 • 413-414 June 2008

12. Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor α and interferon α.

R Bergman, M Ramon, G Willdbaum, E AvitanHeresh, E Mayer, A Shemer, N Karin

J dermatol Sience 56 (2009)163-167

13.Nousbeck J,Sarig O, Avidan n, Idelman M, Bergman R, Ramon M, Enk CD, Sprecher E. IGBP -7 regulates keratinocyte proliferation, differentiation and apoptosis. J Invest Dermatol,in press

14. Atopic dermatitis (AD) keratinocytes exhibit normal Th17 cytokine responses

Kristine E. Nograles, MD,1 Mayte Suárez-Fariñas, PhD,1 Avner Shemer, MD,2 Judilyn Fuentes-Duculan, MD,1 Andrea Chiricozzi, MD,1,3 Irma Cardinale, MSc,1 Lisa C. Zaba, MD, PhD,1 Toyoko Kikuchi, MSc,1 Michal Ramon, MD,4 Reuven Bergman, MD,4 James G. Krueger, MD, PhD,1 and Emma G e2uttman-Yassky, MD, MSc1,5

J Allergy Clin Immunol. 2010 Mar; 125(3): 744–746.

15. IL-22 producing “T22” T-cells account for up-regulated IL-22 in atopic dermatitis (AD), despite reduced IL-17 producing Th17 T-cells

Kristine E. Nograles, MD,1,* Lisa C. Zaba, PhD,1,* Avner Shemer, MD,2 Judilyn Fuentes-Duculan, MD,1 Irma Cardinale, MSc,1 Toyoko Kikuchi, MSc,1 Michal Ramon, MD,3 Reuven Bergman, MD,3 James G. Krueger, MD PhD,1 and Emma Guttman-Yassky, MD MSc

J Allergy Clin Immunol. 2009 Jun; 123(6): 1244–52.e2.

J Eur Acad Dermatol Venereol. 2020 Jan 9. doi: 10.1111/jdv.16187. [Epub ahead of print]Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.Poulin Y, Ramon M, Rosoph L, Weisman J, Mendelsohn AM, Parno J, Rozzo SJ, Lee

Follicular Eruption With Folliculotropic Lymphocytic Infiltrates Associated With Iatrogenic Immunosuppression: Report and Study of 3 Cases, and Review of the Literature.Avitan-Hersh E, Dias-Polak D, Ramon M, Sahar D, Magen D, Pollack S, Bergman R.Am J Dermatopathol. 2019 Nov 26. [Epub ahead of print]

Enhanced Itch Intensity Is Associated with Less Efficient Descending Inhibition Processing for Itch But Not Pain Attenuation in Chronic Dermatology PatientsGranot M, Yakov S, Ramon M.Pain Med. 2019 Oct 23. pii: pnz263. doi: 10.1093/pm/pnz263. [Epub ahead of print]

Cutan Pathol. 2020 Feb;47(2):113-120. doi: 10.1111/cup.13588. Epub 2019 Oct 27

Follicular eruption with folliculotropic lymphocytic infiltrates associated with anti-tumor necrosis factor alpha therapy: Report and study of 3 cases.

Avitan-Hersh E1,2, Dias-Polak D1, Ramon M1, Zaaroura H1, Sahar D3, Bergman

Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.David M, Gospodinov DK, Gheorghe N, Mateev GS, Rusinova MV, Hristakieva E, Solovastru LG, Patel RV, Giurcaneanu C, Hitova MC, Purcaru AI, Horia B, Tsingov II, Yankova RK, Kadurina MI, Ramon M, Rotaru M, Simionescu O, Benea V, Demerdjieva ZV, Cosgarea MR, Morariu HS, Michael Z, Cristodor P, Nica C, Silverman MH, Bristol DR, Harpaz Z, Farbstein M, Cohen S, Fishman P.

J Drugs Dermatol. 2016 Aug 1;15(8):931-8.

Does infection play a role in the pathogenesis of granuloma annulare?

Avitan-Hersh E, Sprecher H, Ramon M, Bergman

J Am Acad Dermatol. 2013 Feb;68(2):342-3

J Eur Acad Dermatol Venereol. 2012 Mar;26(3):361-7 Epub 2011 Apr 20.

Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial.

David M1, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, Yankova R, Kouzeva V, Ramon M, Silverman MH, Fishman P.

Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-alpha and interferon-alpha.

Bergman R, Ramon M, Wildbaum G, Avitan-Hersh E, Mayer E, Shemer A, Karin N.

J Dermatol Sci. 2009 Dec;56(3):163-7. doi: 10.1016/j.jdermsci.2009.08.006. Epub 2009 Oct 2.

Isr Med Assoc J. 2008 Jun;10(6):413-4.

Efficacy of tildrakizumab by patient demographic and

disease characteristics across a phase 2b and 2 phase 3

trials in patients with moderate-to-severe chronic plaque

psoriasis

Y. Poulin, M. Ramon,L. Rosoph,J. Weisman,A.M. Mendelsohn,

J. Parno,,S.J. Rozzo,P. Lee

JEADV july2020

Catastrophizing thinking toward itch and pain in chronic itch patients

JEAD sept 2020

Title:

Lecture 1: Nail psoriasis Management in the elderly patients

Abstract:

Treating elderly patients has become common in daily clinical practice.

Nail physiology is altered in this population.

Psoriasis is a prevalent skin disease in older adult patients. It commonly involves the nails especially in association with psoriatic arthritis and long standing psoriasis. Nail psoriasis greatly impacts patients’ quality of life and self-esteem.

Diagnosing nail psoriasis in elderly individuals may be challenging because physiologic age-related nail changes are common.

Treating nail psoriasis in the geriatric population may be challenging. General nail care measures may prevent exacerbations. Topical therapy is relatively effective, with a low rate of adverse events. Systemic treatments and biologics are alternatives for nails and skin involvement.

Prof. Yuval Ramot

Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel

Bio:

Yuval Ramot, MD, MSc

Associate Professor of Dermatology and Venereology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel

Yuval Ramot is an Associate Professor of Dermatology in the Hebrew University and is the director of the psoriasis and hidradenitis suppurativa clinics in Hadassah Medical Center. His research focuses on inflammatory skin conditions, genetic skin and hair diseases, and toxicology of the skin. He is a member of the European Hair Research Society and Israel Society of Dermatology and Venereology boards. In addition, he is part of the Editorial Board of Experimental Dermatology, Skin Health and Disease and JEADV Clinical Practice. He has co-authored more than 10 chapters in books and more than 180 articles in peer-reviewed journals.

.

Title:

Lecture 1: Nail psoriasis and fungal infections

Lecture2 : The mechanism of nail psoriasis

Abstract:

Abstract 1

The Faculty of Medicine, Hebrew University of Jerusalem and the Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel

The connection between nail psoriasis and onychomycosis is still a matter of debate, and the relationship between these two entities is still under scrutiny. In psoriasis, the changes in the capillaries of the nail together with the defects in the nail plate, can lead to susceptibility to infections. Furthermore, onycholysis, a common feature of nail psoriasis, can result in a humid environment, that may enhance fungal proliferation. This, together with the use of immunosuppressive medications, can lead to increased vulnerability to fungal infection. In this talk, the incidence and pathogenesis of dermatophyte infection in nail psoriasis will be discussed.

Lecture 2

Nail psoriasis is a common condition, affecting between 50-79% of psoriasis patients and up to 80% of psoriatic arthritis patients. The pathogenesis of this condition is not entirely elucidated, although we know that there are common inflammatory pathways between nail psoriasis and the skin. Involvement of the different compartments of the nail can result in different clinical phenotypes: disease of the nail bed leads to oil-drop discoloration, onycholysis, splinter hemorrhages and subungual hyperkeratosis, while involvement of the nail matrix results in red spots in the lunula, pitting, nail plate crumbling and leukonychia. This talk will discuss the pathogenesis and mechanism of nail psoriasis, with emphasis on the recent developments in our understanding of this condition.

Dr. Waseem Shehadeh

Division of Dermatology, Tel Aviv Sourasky Medical Center, Israel

Bio:

Dr Waseem Shehadeh is a senior physician in the laser and advanced technologies unit at the Tel Aviv Medical Center's Dermatology and Venereology division.

Dr Waseem Shehadeh is a graduate of the Rappaport Faculty of Medicine at the Technion and has completed his residency in the Tel-Aviv Medical Center's division of dermatology, where his research focuses on utilizing advanced technologies for the treatment of dermatologic diseases.

Title:

Lecture 1: Ingrown nail treatment: laser vs surgical

Lecture 2:Treatment of Nail Psoriasis with A Combination of Pulse-Dye Laser (PDL) and Fractional Ablative CO2 Laser (FACL) - Assisted Betamethasone - Calcipotriol Gel Delivery

Abstract:

Abstract 1

A literature review of the different treatment variations for onychocryptosis.

Abstract 2

Background: Nail psoriasis is a common and potentially debilitating condition for which no effective and safe nonsystemic therapy is currently available. Recently, laser-assisted drug delivery (LADD) is being increasingly used to facilitate transcutaneous penetration of topical treatments.

Objectives: We set to assess the efficacy and safety of combined pulse-dye laser and fractional CO2 laser-assisted betamethasonecalcipotriol gel delivery for the treatment of nail psoriasis.

Material and methods: We conducted a prospective, intrapatient comparative study in a series of 22 patients with bilateral fingernail psoriasis. Nails on the randomized hand were treated with 3 monthly sessions of pulse-dye laser to the proximal and lateral nail folds followed by fractional ablative CO2 laser to the nail plate. Between treatments and one month following the last treatment, the participants applied betamethasone propionate-calcipotriol gel once daily to the nail plate. Clinical outcome was ascertained using nails photography, the Nail Psoriasis Severity Index (NAPSI) and patient satisfaction.

Results: Seventeen completed the study. Three participants withdrew from the study because of treatment-associated pain. Treatment was associated with a statistically significant improvement of the NAPSI scale (p < .002). Patient satisfaction was high.

Conclusion: Combined PDL and fractional ablative CO2-LADD of betamethasone-calcipotriol gel should be considered for the treatment of nail psoriasis.

Prof. Eli Sprecher

Division of Dermatology, Tel Aviv Medical center, Israel

Bio:

Eli Sprecher chairs the Division of Dermatology at the Tel Aviv Sourasky Medical Center where he also serves as Deputy Director for Research and Development. He is Frederick Reiss Professor of Dermatology at the Medical School, Tel Aviv University. He received an MD degree from the Hebrew University, a PhD degree in Molecular Virology from the Hebrew University and an MBA degree from Tel Aviv University. He also spent a post-doctoral fellowship in Human Genetics at the Thomas Jefferson University, Philadelphia. His research focuses on the genetic basis of skin diseases. He has co-authored over 350 scientific publications, has earned several patents, and has received numerous national and international prizes and honors.

Title:

Lecture 1:
Inherited disorders of the nail unit: from genes to patient care

Abstract:

Abstract 1

The past years have witnessed dramatic advances in our understanding of the genetic basis of hereditary nail disorders. Through the study of these conditions, we have gained much insight into the nature and role of key mediators of nail growth and differentiation. This new knowledge has not only far reaching implications for the counseling of individuals at risk for inherited nail diseases, it often bears critical implications for the management of those patients.

Dr. Ganna Stovbyr

Dermatologist, leading specialist in foot and nail pathology at "EuroDerm" clinic, Kyiv, Ukraine

Bio:

Dermatologist, leading specialist in foot and nail pathology at "EuroDerm" clinic (Kyiv, Ukraine), president of “ Ukrainian Society of Foot and Nail Pathology".

Main areas of interest: personalised approach to diagnosis and treatment of foot and nail pathologies in children and adults, general dermatology.

Active participant of many international conferences, among them: International Summer Academy of Practical Dermatology in Munich (2011); EADV (European Academy of Dermatovenereology) Nail Surgery Courses Brussels, Belgium 2017; Congress of the American Academy of Dermatology(AAD) 2014 (USA; Denver); 2019 (USA, Washington); 23rd Annual Meeting of the AAD Council on Nail Problems, 2019, Washington, DC; DermFoot 2019 Podiatry Congress Tysons, Virginia, USA; "First International Conference on Nail Pathology" Tel Aviv, Israel (2019).

Organizer and speaker at the conference "Kyiv Podological Days" (2019; 2021); and many other activities for dermatologists and doctors of other specialties.

Consultant-dermatologist of the TV channel "STB" and the TV-program "I am ashamed of my body".

Title:

Lecture 1: Conservative and/or Surgical Approach for Pincer Nails and Ingrown Toenails

Abstract:

Conservative and/or Surgical Approach for Ingrown Toenails and Pincer Nails

Eckart Haneke^1,2,3 & Anna Stovbyr⁴

¹Department of Dermatology, Inselspital, University of Berne, Bern, Switzerland

²Dermatology Practice Dermaticum. Freiburg, Germany

³ Centro de Dermatología Epidermis, Instituto CUF, Matosinhos, Porto, Portugal

⁴Klinik Evroderm, Kiew, Uktaine

Ingrown toenails (unguis incarnatus, onychocryptosis) and pincer nails (transverse overcurvature, trumpet nail, omega nail, unguis constringens) are very common. Ingrown toenail occur in different clinical varieties and at any age.

In the newborn, they are due to short nails that have not yet overgrown the tip of the big toe. They are treated by gentle massage of the toes in warm bath.

A hypertrophic lateral or medial lip is an inborn hypertrophy of one or both lateral nail folds. Again, the first treatment is gentle massage. If this is not successful, the hypertrophic fold may be removed with an electric loop, which takes some seconds to do. The small wound rapidly heals by secondary intention.

Congenital malalignment of the big toenail is not so rare. The nail’s long axis is deviated laterally in relation to the axis of the distal phalanx. This may have no further consequences or may be associated with discoloration of the nail, transverse ridging, thickening of the plate, a triangular shape with medial kinking of the plate. In these cases, gently probing under the plate reveals very marked onycholysis, which is the single most important prognostic factor. Cutting the onycholytic plate back demonstrates a distal bulge and an extremely short nail bed. The initial treatment should be conservative with taping to redress the distal bulge, correct the distal interphalangeal hallux valgus and the nail growth direction. If this is done by the parents there is a very good chance of improvement. When this fails after consistent treatment of at least two years surgery may be performed to rotate the axis of the nail into that of the distal phalanx.

The most common type of unguis incarnatus is seen in school children, adolescents and young adults. The nail is wide, usually markedly curved, the lateral-distal edge has pierced the distal nail groove and caused granulation tissue. Conservative therapy is by taping, packing, gutter insertion, nail braces and many more techniques and has a good success rate when performed consistently. However, patient counseling to avoid recurrences is of utmost importance. If this fails surgery is indicated. In our hands and now world-wide, narrowing of the nail plate by selective segmental matrix horn ablation is the treatment of choice. This may be done by chemical cautery with 88% phenol, which has a success rate of 99% in experienced hands. Altrnatives are 10% sodium hydroxide and 85 – 100% trichloracetic acid. The postoperative care is very important as this is what has the biggest influence on the healing time. If there is a very marked hypertrophy of the lateral nail folds, they may be reduced with radical excision according to Vandenbos or with the super-U technique. These techniques do not narrow the nail matrix.

Pincer nails are characterized by a distally increasing transverse overcurvature of toenails. The genetic type shows symmetric involvement of the big toenails associated with lateral deviation and often also of some lesser toenails then associated with medial deviation. The cause is a widening of the base of the distal phalanx by lateral osteophytes on the condyles of the distal phalanx. In mild forms, unbending the nails with nail braces and a variety of other orthonyx devices is helpful. However, as this is not a therapy according to the pathomechanism the braces have virtually to be kept years if not life-long. Surgery of moderate cases aims at taking the outward pressure on the root of the nail away by bilateral matrix horn cautery. Severe cases require an additional nail bed plasty to flatten the pinched nail bed. If the curvature exceeds 360° and is symptomatic complete nail phenolization may be performed.

Prof. Dimitris Rigopoulos

Professor of Dermatology-Venereology Chair of the 1st Department of Dermatology-VenereologyNational and Kapodistrian University of Athens, Medical School, Sygros Hospital
Greece

Bio:

Professor Rigopoulos graduated from the Medical School of the National and Kapodistrian University of Athens Greece. He performed his residency in Dermatology-Venereology at Sygros Hospital, he was trained in Lasers and Dermo-surgery at the Northwestern University of Chicago. He was elected as Lecturer at the National Kapodistrian University of Athens, Medical School, then as Assistant Professor, Associate Professor and finally as Full Professor of Dermatology.

He is Member of the European Academy of Dermatology, of the American Academy of Dermatology, of the American Dermatological Association , of the International Society of Dermatology.

He was the Past President of the Council for Nail Diseases (USA) and he is the President of the European Nail Society.

He is the President of the Hellenic Society of Dermatology and Venereology since 2010.

He has published 200 peer reviewed papers, he is the author of 10 books, 20 chapters in books and has participated in 30 clinical trials. He is invited speaker in many European and International Congresses and Meetings.

He is the founder and one of the two Editors of the Skin Appendage Disorders Medical Journal, Published by S. Karger AG, Basel, Switzerland.

Title:

Lecture 1: Clinical Features of Nail Psoriasis

Lecture 2: Update on the management of nail management of nail psoriasis

Abstract:

Abstract 1

Psoriasis affects almost 60% of patients with cutaneous psoriasis and almost 90% of patients with psoriatic arthritis.

Clinical signs depend on the area of the nail unit that is affected by the disease and some cases, diagnosis can be difficult for the clinician, especially when nails are the only part of the skin affected.

In this presentation, all the clinical signs of Nail Psoriasis will be presented in a way to help clinical dermatologists to differentiate the disease.

Abstract 2

Nail Psoriasis affects almost 60% of patients with cutaneous disease, equally male and female patients and in the majority of the cases clinical signs appear both on hands and feet.

Treating the disease is rather difficult and always a challenge for the clinician.

In this presentation, management of Nail Psoriasis will be discussed and all new treatment improvements will be mentioned.

Prof. Phoebe Rich

Oregon Health and Science University, and Oregon Dermatology and Research

Bio:

Professor Phoebe Rich

Adjunct Professor of Dermatology at Oregon Health & Science University, Portland Oregon

Phoebe Rich MD is Adjunct Professor and Director of the Nail Disorder Clinic at Oregon Health & Science University Dermatology at Oregon Health & Science University. Her academic interest is in all aspects of nail disorders, and she lectures nationally and internationally on that topic. She has participated as Principal Investigator in over 200 clinical trials at Oregon Dermatology and Research Center over the past 25 years.

Dr. Rich served on the Board of Directors of the American Academy of Dermatology, and is a member of the Oregon Dermatology Society, Women’s Dermatology Society, American Society of Dermatologic Surgery, International Dermatology Society, American Dermatologic Society, European Nail Society, and the Council for Nail Disorders. She takes pleasure in mentoring and teaching residents and medical students about nail disorders.

In her spare time Phoebe enjoys beekeeping, along with fishing and crabbing at the Oregon coast.

Title:

Lecture 1: Gel Lacquer Polish, mechanism of the pathogenesis, complications and therapeutic approach

Lecture 2: Onychomycosis in Children – An Update

Abstract:

Abstract 1

Phoebe Rich MD

Adjunct Professor Dermatology and Director of the Nail Disorder Clinic

Oregon Health & Science University

Portland, Oregon

Esthetic enhancement of fingernails and toenails is a common practice worldwide. Gel nail polish has become very popular in the past few years, and although mostly safe for many people, there are potential problems and concerns physicians to know in order keep their patients safe in the nail salon.

Complications with gel nail polish and other gel nail enhancements can be divided into 3 categories

allergic contact dermatitis to the ingredients in the gel polish substrate material ingredients
1. 2-hydroxypropyl methacrylate (HPMA)
2. 2-hydroxyethyl methacrylate (HEMA).
3. Tetrahydrofurfuryl methacrylate (THFMA)
4. 2-Hydroxyethyl acrylate (HEA) and
5. ethylene glycol dimethacrylate (EGDMA)
Mechanical damage to the natural nail plate due to trauma during preparation, application, and removal of the product
The potential threat of UV induced skin lesions on dorsal hands and feet from exposure to the UV light used to cure the gel product to a hard durable finish.

Dermatologist awareness of these potential issues can help patients avoid pitfalls through education.

Abstract 2

Phoebe Rich MD

Adjunct Professor Dermatology and Director of the Nail Disorder Clinic

Oregon Health & Science University

Portland, Oregon

Ten points about onychomycosis in children that everyone should know

Onychomycosis in children is relatively uncommon with a prevalence of 0.14% compared to 6.4% in adults, although the prevalence in children is rising world-wide.
Nail disorders in children are not fungal 85% of the time and fungal only 15 % of the time. Therefore, meticulous confirmation using the standard tools of KOH, Culture, PAS staining of clippings, and PCR is crucial for accurate diagnosis.
Trichophyton rubrum is the most common organism found in the toenails of children. However, in young children, fingernails are more commonly involved than toenails and candida is the usual etiologic agent.
Common predisposing factors for onychomycosis in children are a positive family history of nail fungus, nail trauma, concomitant of tinea pedis, immunosuppression, and inherited immunodeficiencies.
Topical medications for OM in children are usually first line. There is solid data supporting the use of efinaconazole, tavaborole and ciclopirox in children, and these drugs have regulatory approval for use in differing pediatric 4 age groups.
Although oral antifungal drugs (terbinafine, itraconazole, fluconazole) have sparse evidence-based data in children, they are frequently used off-label and are considered to be effective and safe when used in accepted weight-based dosing schedules and with appropriate safety cautions.
Prevention of relapse and recurrence strategies for OM in children hinge on educating the child and family about avoiding exposure in high-risk areas where others walk barefoot, and vigilant feet, sock, and shoes hygiene.
Although data is limited, prophylactic use of topical antifungal medications preventatively may be helpful in warding off relapse and reinfection of onychomycosis in children.

Prof. Adam I. Rubin

Associate Professor of Dermatology, Pediatrics, and Pathology and Laboratory Medicine at the Perelman School of MedicineUniversity of Pennsylvania
USA

Bio:

Adam I. Rubin, MD is an Associate Professor of Dermatology, Pediatrics, and Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. There he directs the adult and pediatric nail clinics, and practices at The Children’s Hospital of Philadelphia, and the Hospital of the University of Pennsylvania. Dr. Rubin specializes in nail disorders, nail surgery, and histopathology of the nail unit. Dr. Rubin is the lead editor for the 4th edition of Scher and Daniel’s Nails: Diagnosis, Therapy, Surgery, published in 2018. He is an author of the 3rd edition of the Atlas and Synopsis of Lever's Histopathology of the Skin, and an associate editor of the 11th edition of Lever's Histopathology of the Skin. At the Children’s Hospital of Philadephia he is the pediatric dermatopathologist, and a member of the largest pediatric dermatology group in the United States. He is an Associate Editor for the Journal of Cutaneous Pathology, where he focuses on nail pathology and pediatric dermatopathology. He is an Assistant Editor for the journal Dermatologic Surgery, where he focuses on nail surgery. Dr. Rubin is also an Assistant Section Editor for JAMA Dermatology. He serves on multiple other editorial boards including the Journal of the American Academy of Dermatology, The American Journal of Dermatopathology, Skin Appendage Disorders, and Dermatology Practical and Conceptual. Dr. Rubin is a current board member of the Council for Nail Disorders and The European Nail Society, and is a member of the Executive Committee of the International Society for Dermatopathology. Dr. Rubin is the current Secretary-Treasurer of the Council for Nail Disorders and a co-director of the annual European Nail Society Nail Histopathology Workshop.

Title:

Lecture 1: Advances in Nail Pathology

Lecture 2: Interpretation of Nail Biopsies with Emphasis on the Location and Size of the Biopsy Required to Establish the Most Accurate Diagnosis

Abstract:

Abstract 1

This lecture will update attendees on the latest information on nail unit histopathology. The focus of the lecture is on nail unit melanocytic neoplasms. New information regarding melanocytes and melanocyte remnants in the nail plate will be discussed, including their relationship to associated diagnoses of nevi, melanoma in situ, and invasive malignant melanoma in the nail unit. We will further discuss new information regarding the genetics of nail unit melanoma and its comparison to acral melanoma, and how this new data demonstrates that these two classes of melanoma have distinct mutational profiles, which have strong implications for differences in therapy and pathogenesis. While nail melanocytic lesions have been traditionally grouped with acral melanocytic lesions, this new data demonstrates that going forward, they should be considered as separate entities. A new clinicopathologic entity of subungual melanoma with blue nevus like features will be discussed, that demonstrates challenging histopathologic diagnostic features.

Abstract 2

This lecture approaches considerations on how to best select biopsy techniques based on the clinical presentations of select inflammatory and neoplastic nail unit disorders. By analyzing the clinical presentation of inflammatory disorders, attendees will be best able to select the ideal locations for nail unit punch biopsies, as well as when to consider more advanced techniques including lateral longitudinal excisions. For neoplastic nail unit disorders, we will consider a variety of diagnoses which present with erythronychia, as well as melanonychia, and evaluate when longitudinal excisions, matrix tangential excisions, or punch biopsies would provide the most information, balanced by the best surgical outcome for a particular patient’s presentation.

The 2nd
International Conference on Nail Disorders 2022

Welcome

Invited Speakers